Dilor-G Alternatives Compared
| Dilor-G (dyphylline / guaifenesin) | Xolair (omalizumab) | Dupilumab |
|
|---|
| Dilor-G (dyphylline / guaifenesin) | Xolair (omalizumab) | Dupilumab |
|
|---|---|---|---|
|
Prescription only
Prescribed for Asthma, Bronchitis. Dilor-G may also be used for purposes not listed in this medication guide. |
Prescription only
Xolair is an injectable preparation that works by preventing IgE from binding to IgE receptors on mast cells and basophils and may be used to treat allergic asthma, nasal polyps, chronic idiopathic... View more |
Prescription only
Prescribed for Chronic Rhinosinusitis With Nasal Polyps, Eosinophilic Esophagitis, Eczema, Prurigo Nodularis, Asthma - Maintenance, Atopic Dermatitis, Asthma, COPD. Dupilumab may also be used for... View more |
Related suggestions |
| More about (dyphylline / guaifenesin) | More about Xolair (omalizumab) | More about Dupilumab | |
| Ratings & Reviews | |||
|
Be the first to share your experience with this drug. |
Xolair has an average rating of 7.6 out of 10 from a total of 223 ratings on Drugs.com. 68% of reviewers reported a positive effect, while 18% reported a negative effect. |
Dupilumab has an average rating of 7.2 out of 10 from a total of 503 ratings on Drugs.com. 60% of reviewers reported a positive effect, while 21% reported a negative effect. |
|
| Drug Class | |||
| Side Effects | |||
| Generic Availability | |||
|
N/A |
N/A |
N/A |
|
| Pricing and Coupons * Prices are without insurance | |||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
| Dosage Forms Available | |||
|
N/A |
|
N/A |
|
| Brand Names | |||
| Other dyphylline / guaifenesin brands include: D-G, Difil G, Difil-G Forte, Dilex-G, Dilex-G 200, Dilex-G 400, Dy-G, Dyfilin GG, Dyflex-G, Dyline GG, Dyphyl GG, Dyphyllin-GG, Dyphylline GG, Dyphylline GG ES View more |
N/A |
Dupixent | |
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | |||
|
2 hours |
624 hours |
N/A |
|
| CSA Schedule ** View glossary of terms | |||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
|
| Pregnancy Category | |||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
|
| Drug Interactions | |||
|
A total of 108 drugs are known to interact with Dilor-G:
|
A total of 25 drugs are known to interact with Xolair:
|
A total of 89 drugs are known to interact with Dupilumab:
|
|
| Alcohol/Food/Lifestyle Interactions | |||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
| Disease Interactions | |||
| First Approval Date | |||
|
N/A |
June 20, 2003 |
N/A |
|
| WADA Class View World Anti-Doping Agency classifications. | |||
|
N/A |
N/A |
N/A |
|
| More Information | |||
| Patient resources | |||
|
N/A |
|||
| Professional Resources | |||
|
N/A |
|||
| Related Treatment Guide | |||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.